Please login to the form below

Not currently logged in
Email:
Password:

mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

New data backs Merck’s segue into MS with BTK inhibitor

New data backs Merck’s segue into MS with BTK inhibitor

drug, which is already used for relapsed or refractory mantle cell lymphoma (MCL).

Latest news

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    The star in oncology for AZ is non-small cell lung cancer (NSCLC) therapy Tagrisso (osimertinib), which grew 95% to $1.86bn last year, thanks to a move up the treatment ... cell lymphoma, along with new MEK inhibitor selumetinib in neurofibromatosis type

  • Celgene’s Revlimid gets a win in late-stage lymphoma Celgene’s Revlimid gets a win in late-stage lymphoma

    Celgene is planning to file for approval of Revlimid in the new indication early next year, adding to its current uses in multiple myeloma, mantle cell lymphoma, and anaemia associated with ... An earlier read-out in diffuse large B-cell lymphoma (DLBCL)

  • Another R&D flop for Incyte, but Jakafi keeps delivering Another R&D flop for Incyte, but Jakafi keeps delivering

    Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

  • AZ expects return to growth this year after 2017 decline AZ expects return to growth this year after 2017 decline

    Mantle cell lymphoma therapy Calquence has a long way to go before it can challenge main rival Imbruvica (ibrutinib) from Johnson &Johnson/AbbVie, but according to AZ is picking up 20%

  • Celgene gains French reimbursement for Revlimid in multiple myeloma Celgene gains French reimbursement for Revlimid in multiple myeloma

    It’s been approved in combination with dexamethasone as a first-line treatment for multiple myeloma in patients who are not eligible for autologous stem cell transplant. ... However, HAS handed Revlimid ASMR V status, equating to ‘no improvement’

More from news
Approximately 2 fully matching, plus 56 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Body image and mental health: The psoriasis connection
As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
It’s not the end of the world, is it?
Industry change isn’t always gradual – it can be apocalyptic...

Infographics